Physician profile
Chandra Shekar
NPI 1881889624
$3,077.54
in general payments reported to CMS, 2019-2025
32 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $377 · 2021: $484 · 2022: $556 · 2023: $672 · 2024: $263 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.91 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $343.29 | 2021-2023 | Acthar |
| Upsher-Smith Laboratories LLC | $290.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $280.83 | 2019-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Abbvie INC. | $253.74 | 2021-2023 | Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $228.20 | 2019-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $174.85 | 2022-2023 | |
| Glaxosmithkline, LLC. | $171.53 | 2021-2025 | Trelegy Ellipta |
| Abbott Laboratories | $150.97 | 2023 | Infinity |
| Kowa Pharmaceuticals America, INC. | $145.95 | 2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $138.80 | 2019-2020 | |
| Verona Pharma, INC. | $119.47 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $103.42 | 2019-2025 | Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $77.01 | 2020 | |
| Ani Pharmaceuticals, INC. | $60.10 | 2023-2024 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.58 | 2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.09 | 2019-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $49.47 | 2019 | |
| Merck Sharp & Dohme LLC | $49.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.94 | 2025 | Glassia |
| Allergan, INC. | $36.46 | 2019-2020 | |
| Assertio Therapeutics, INC. | $35.35 | 2019 | |
| Vapotherm INC | $34.34 | 2022 | |
| Eisai INC. | $29.54 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $19.27 | 2024 | Ingrezza |
| Tris Pharma INC | $19.18 | 2024 | Dyanavel Xr |
| Novo Nordisk INC | $19.14 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.25 | 2023 | Nuzyra |
| Exact Sciences Corporation | $17.47 | 2025 | Cologuard Collection Kit |
| Kvk-Tech, INC. | $16.93 | 2019 | |
| Csl Behring | $16.79 | 2023 | Kcentra |
| 3b Medical, INC. | $15.68 | 2023 | Luna |
| Medline Industries Lp | $15.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Shekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.